Making the leap from the lab to the boardroom

Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.

By Alexandra Pecci • March 21, 2023

SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape

Although many pharma and biotech companies had deposits at the failed bank, most have reported little to no exposure.

By Michael Gibney • March 21, 2023

Explore the Trendline➔

Cell and gene therapies

How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

By PharmaVoice staff

This biotech’s ‘Microsoft’ approach could change how we see gene therapy

The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.

By Karissa Waddick • March 20, 2023

‘The Last of Us’ might be fiction, but fungi are a looming threat

Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.

By Kelly Bilodeau • March 20, 2023

A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

By Taren Grom • March 17, 2023

In the fallout from Aduhelm, Biogen’s leadership shakeup continues

The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

By Karissa Waddick • March 16, 2023

Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.

By Michael Gibney • March 16, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

The power of connections for a startup CEO

Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

By Alexandra Pecci • March 14, 2023

A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

By Michael Gibney • March 14, 2023

Biden doubles down on drug pricing in 2024 budget — but boosts R&D

The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.

By Karissa Waddick • March 13, 2023

Babson aims to shed Theranos curse with new blood testing tech

Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

By Kelly Bilodeau • March 13, 2023

While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

By Karissa Waddick • March 9, 2023

Woman of the Week: Lucy Therapeutics’ Amy Ripka

How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.

By Taren Grom • March 8, 2023

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

3 keys to good storytelling in pharma

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

By Alexandra Pecci • March 7, 2023

Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?

By Michael Gibney • March 7, 2023

FDA ups generics and biosimilar approvals for a shot at lower drug costs

As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022. 

By Karissa Waddick • March 6, 2023

Why layoffs are not the answer to biopharma’s troubled market

As companies look to cut costs, an EY analyst urges them to consider not cutting staff.

By Kelly Bilodeau • March 6, 2023

PharmaVoice 100 honorees: Where are they now?

How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

By Taren Grom , Karissa Waddick • March 3, 2023

Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

By Taren Grom • March 2, 2023

The ‘recovering academic’ leading Allogene to the next stage of cell therapy

Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

By Michael Gibney • March 2, 2023

Woman of the Week: Denali Therapeutics’ Cindy Dunkle

As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.

By Taren Grom • March 1, 2023

Do R&D costs justify the price of drugs? Nope, new study says

A BMJ study found that spending on drug sales vastly outstripped spending on drug development.

By Alexandra Pecci • March 1, 2023

Multimillion-dollar therapies are changing how payers foot the bill

With more gene therapies headed to market, novel payment methods are emerging from regulators and academia. 

By Meagan Parrish • Feb. 28, 2023